Go Deep
Glenmark Pharmaceuticals Limited
Glenmark Pharmaceuticals Limited Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Sep 2026 | 20,277 | 36.5 | 6.55 | 0.06 | 2,441.50 |
| Oct 2026 | 20,571 | 36.6 | 6.26 | 0.06 | 2,331.00 |
| Oct 2026 | 20,149 | 36.0 | 6.16 | 0.06 | 2,293.00 |
Glenmark Pharmaceuticals Limited Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 39,317,300,000.0 | 37,602,770,000.0 | 38,879,990,000.0 | 60,037,940,000.0 |
| Net Profit | 4,829,240,000.0 | 3,014,140,000.0 | 4,032,130,000.0 | 6,103,530,000.0 |
| EPS | 17.1 | 10.7 | 14.3 | 21.6 |
Glenmark Pharmaceuticals Limited Revenue & Profit: Last 5 Years
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Revenue | 167,114,030,000.0 | 131,458,360,000.0 | 116,354,560,000.0 | 114,319,380,000.0 | — |
| Net Profit | 13,618,510,000.0 | 10,470,970,000.0 | -15,016,680,000.0 | 2,972,450,000.0 | — |
| EPS | 48.3 | 37.1 | -53.2 | 10.5 | — |
Glenmark Pharmaceuticals Limited Balance Sheet
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Total Assets | 199,078,760,000.0 | 160,495,540,000.0 | 143,586,240,000.0 | 193,716,760,000.0 | — |
| Total Liabilities | 93,960,830,000.0 | 72,004,840,000.0 | 65,110,770,000.0 | 95,324,170,000.0 | — |
| Total Equity | 105,121,090,000.0 | 88,494,410,000.0 | 78,479,270,000.0 | 94,739,230,000.0 | — |
Owes vs Owns
Glenmark Pharmaceuticals Limited owed ₹0.47 for every ₹1 it owned in Mar 2026, down from ₹0.49 in Mar 2023.
| Period | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Owes vs Owns | 0.47× | 0.45× | 0.45× | 0.49× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Glenmark Pharmaceuticals Limited Assets & Liabilities Breakdown (₹ Cr)
What it owns — Mar 2026
Cash & short-term investments 6.0%Receivables 24.9%Inventory 17.2%Fixed assets (tangible) 21.8%Intangible assets 12.6%Other assets 17.2%
How it's funded — Mar 2026
Payables 18.8%Other liabilities 28.4%Shareholders' equity 52.8%
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 1,200.8 | 1,691.5 | 1,670.4 | 1,173.3 |
| Receivables | 4,963.4 | 3,341.9 | 1,858.4 | 3,665.2 |
| Inventory | 3,430.8 | 3,028.5 | 2,513.1 | 2,373.6 |
| Fixed assets (tangible) | 4,343.8 | 3,887.9 | 3,567.8 | 4,221.5 |
| Intangible assets | 2,506.2 | 1,460.3 | 1,334.6 | 2,416.3 |
| Long-term investments | 43.1 | 60.5 | 795.8 | 47.3 |
| Other assets | 3,419.8 | 2,579.0 | 2,618.6 | 5,474.5 |
| Liabilities & equity | ||||
| Short-term debt | 0.0 | 1,681.5 | 990.6 | 495.6 |
| Long-term debt | 0.0 | 512.7 | 0.0 | 3,852.1 |
| Payables | 3,743.9 | 3,051.2 | 2,535.9 | 2,000.4 |
| Other liabilities | 5,652.2 | 1,955.1 | 2,984.6 | 3,184.3 |
| Shareholders' equity | 10,511.8 | 8,849.1 | 7,847.5 | 9,839.3 |
| Net tangible assets | 8,005.9 | 7,389.1 | 6,513.4 | 7,057.6 |
Glenmark Pharmaceuticals Limited Cash Flow
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Operating Activities | 34,450,280,000.0 | -8,275,950,000.0 | -2,654,440,000.0 | 6,253,920,000.0 | — |
| Investing Activities | -12,832,330,000.0 | 20,940,000.0 | 45,608,930,000.0 | -5,284,910,000.0 | — |
| Financing Activities | -27,087,480,000.0 | 7,870,450,000.0 | -39,061,270,000.0 | -774,560,000.0 | — |